

Associate, Frankfurt

Corporate



T: 49.69.74220.176
hanna.wacker@skadden.com

Education

Second State Exam, Higher Regional Court of Frankfurt am Main, 2024

First State Exam, University of Dusseldorf, 2021

Bar Admissions

Frankfurt am Main

Languages

English

German

Hanna Wacker focuses her practice on capital markets transactions as well as general securities-related matters.

Ms. Wacker's experience at Skadden includes advising, among others:

Capital Markets (Equity)

- Euronext Brussels and Euronext Amsterdam-listed **ONWARD Medical**, a leading developer of spinal cord injury therapies, in:
 - a €50 million cash capital increase and cornerstone investment by Ottobock SE &Co. KGaA
 - a €52.5 million debt financing from U.S. lender Runway Growth Finance
- **Jefferies** and **BofA Securities** as joint global coordinators and joint bookrunners in connection with capital increases of Zur Rose Group AG

Capital Markets (Equity-Linked/Debt)

- **AGRAVIS** in its offer of up to €60 million in new profit participation rights
- **ONWARD Medical** in connection with a loan agreement

Mergers and Acquisitions

- **CureVac N.V.** in its all-stock acquisition by BioNTech SE that values CureVac N.V. at US\$1.25 billion
- the management and supervisory boards of **Fresenius** in the company's exit from the Austrian and international businesses of VAMED AG
- **Armira** and **Boxine** in Boxine's €1 billion business combination with 468 SPAC I SE, one of the first de-SPAC transactions in the market involving a German-listed blanc cheque company
- **SIGNA Sports United GmbH** in connection with its US\$3.3 billion initial public offering on the New York Stock Exchange as a result of its de-SPAC merger with Yucaipa Acquisition Corporation. The merger also included the acquisition of WiggleCRC Group

Prior to joining Skadden's Frankfurt office, Ms. Wacker worked as a research assistant and completed a legal clerkship in New York.